Removing human immunodeficiency virus (HIV) from human blood using immobilized heparin

Biotechnology Letters

Volumn 34, Issue 5, 2012, Pages 853-856

  Nassar, Roger A ^a   Browne, Edward P ^a   Chen, Jianzhu ^a   Klibanov, Alexander M ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology   (United States)

Author keywords

Adsorption; Detoxification; HIV removal; Human immunodeficiency virus; Immobilized heparin

Indexed keywords

AQUEOUS BUFFER; HUMAN BLOODS; HUMAN IMMUNODEFICIENCY VIRUS; IMMOBILIZED HEPARIN; PHYSICAL SEPARATION; WHOLE BLOOD;

ADSORPTION; BLOOD; DETOXIFICATION; GEL PERMEATION CHROMATOGRAPHY; POLYSACCHARIDES; VIRUSES;

DISEASES;

HEPARIN;

ARTICLE; BLOOD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PROTEIN BINDING; VIROLOGY; VIRUS LOAD; WASTE MANAGEMENT;

BLOOD; DECONTAMINATION; HEPARIN; HIV-1; HUMANS; PROTEIN BINDING; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84860889627     PISSN: 01415492     EISSN: 15736776     Source Type: Journal    
DOI: 10.1007/s10529-011-0840-0     Document Type: Article

References (17)

1. Anon (2005) Editorial: blood supply and demand. Lancet 365: 2151.
2. Bryant BJ, Klein HG (2007) Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 131: 719-733.
3. Bugatti A, Urbinati C, Ravelli C, De Clercq E, Liekens S, Rusnati M (2007) Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 tat and gp120 proteins. Antimicrob Agent Chemother 51: 2337-2345.
4. Cecilia D, Kewal-Ramani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, Zolla-Pazner S (1998) Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol 72: 6988-6996.
5. De Clercq E (2007) The design of drugs for HIV and HCV. Nature Rev Drug Discov 6: 1001-1018.
6. Gebo KA, Fleishman JA, Conviser R, Hellinger J, Hellinger FJ, Josephs JS, Keiser P, Gaist P, Moore RD (2010) Contemporary costs of HIV healthcare in the HAART era. AIDS 24: 2705-2715.
7. Hinrichs WLJ, ten Hoopen HWM, Engbers GHM, Feijen J (1997) In vitro evaluation of heparinized cuprophan hemodialysis membranes. J Biomed Mater Res 35: 443-450.
8. Knipe DM, Howley PM (2001) Fields Virology, 4th edn. Lippincott Williams & Wilkins, Philadelphia.
9. Nakamura H, Miyazaki N, Hosoya N, Koga M, Odawara T, Kikuchi T, Koibuchi T, Kawana-Tachikawa A, Fujii T, Miura T, Iwamoto A (2011) Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir. J Infect Chemother 17: 105-110.
10. Nygren H (1995) Logarithmic growth in surface adsorption. Adv Colloid Interface Sci 62: 137-159.
11. O'Keeffe RS, Johnston MD, Slater NKH (1999) The affinity adsorptive recovery of an infectious herpes simplex virus vaccine. Biotechnol Bioeng 62: 537-545.
12. Qian K, Morris-Natschke SL, Lee K-H (2009) HIV entry inhibitors and their potential in HIV therapy. Med Res Rev 29: 369-393.
13. Segura MDM, Kamen A, Trudel P, Garnier A (2005) A novel purification strategy for retrovirus gene therapy vectors using heparin affinity chromatography. Biotechnol Bioeng 90: 391-404.
14. Smith PK, Mallia AK, Hermanson GT (1980) Colorimetric method for the assay of heparin content in immobilized heparin preparations. Anal Biochem 109: 466-473.
15. Tullis RH, Duffin RP, Zech M, Ambrus JL (2002) Affinity hemodialysis for antiviral therapy. I. Removal of HIV-1 from cell culture supernatants, plasma, and blood. Ther Apher 6: 213-220.
16. WHO and CDC data found on their respective websites (updated in July 2010): http://www. who. int/features/factfiles/hiv/en/index. html and http://www. cdc. gov/hiv/resources/factsheets/us. htm.
17. Zahn A, Allain JP (2005) Hepatitis C virus and hepatitis B virus bind to heparin: purification of largely IgG-free virions from infected plasma by heparin chromatography. J Gen Virol 86: 677-685.